Kintara Therapeutics Inc
0.00 (0.0%)
Volume 0
Bid Price 4.84
Ask Price 9.10
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
Kintara Therapeutics Inc KTRA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 6.99 04:00:08
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
0 0 - 3.5022 - 42.00
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 6.99 USD


Draw Mode:

Kintara Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 11.30M 1.62M 1.61M $ - $ - -27.50 -0.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 4.48M 3.50%

more financials information »

Kintara Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical KTRA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week6.707.655.916.4427,9700.294.33%
1 Month8.018.47775.596.8631,020-1.02-12.73%
3 Months4.4515.49993.50225.93564,2652.5457.08%
6 Months18.3520.003.50227.832,002,847-11.36-61.91%
1 Year21.5842.003.502210.922,183,554-14.59-67.61%
3 Years60.50167.503.502235.041,470,076-53.51-88.45%
5 Years60.50167.503.502235.041,470,076-53.51-88.45%

Kintara Therapeutics Description

Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The Company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.